Naris Nilubol

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. pmc Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin
    Naris Nilubol
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Thyroid 23:695-702. 2013
  2. doi request reprint Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy
    Naris Nilubol
    Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC1201 Room 3 3940, Bethesda, MD 20892 1201, USA
    World J Surg 37:1966-72. 2013
  3. pmc Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening
    Naris Nilubol
    Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, MSC 1201, Bethesda, MD 20892, USA
    J Transl Med 10:198. 2012
  4. doi request reprint Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit?
    Naris Nilubol
    Endocrine Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC1201 Rm 3 3940, Bethesda, MD 20892 1201, USA
    World J Surg 36:1368-74. 2012
  5. doi request reprint Molecular pathways associated with mortality in papillary thyroid cancer
    Naris Nilubol
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Surgery 150:1023-31. 2011
  6. pmc Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions
    Samira M Sadowski
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md Electronic address
    J Am Coll Surg 218:997-1003. 2014
  7. pmc Association of type-O blood with neuroendocrine tumors in multiple endocrine neoplasia type 1
    Allison B Weisbrod
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 98:E109-14. 2013
  8. pmc MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors
    Dhaval Patel
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md Electronic address
    Surgery 154:1224-8; discussion 1229. 2013
  9. pmc Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype
    Ryan J Ellis
    Endocrine Oncology Branch R J E, M B, D P, N N, M H, L Z, E K, Genetics Branch Y W, H S S, S D, D C E, P S M, and Laboratory of Pathology M J M, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 and Perelman School of Medicine R J E, University of Pennsylvania, Philadelphia, Pennsylvania 19104
    J Clin Endocrinol Metab 99:E329-37. 2014
  10. pmc Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor
    Sahzene Yavuz
    Diabetes, Endocrine and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:1834-41. 2012

Collaborators

Detail Information

Publications27

  1. pmc Multivariate analysis of the relationship between male sex, disease-specific survival, and features of tumor aggressiveness in thyroid cancer of follicular cell origin
    Naris Nilubol
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Thyroid 23:695-702. 2013
    ..Thus, using a large population-based database, we sought to better characterize the role of sex in disease aggressiveness and outcome...
  2. doi request reprint Utility of intraoperative parathyroid hormone monitoring in patients with multiple endocrine neoplasia type 1-associated primary hyperparathyroidism undergoing initial parathyroidectomy
    Naris Nilubol
    Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC1201 Room 3 3940, Bethesda, MD 20892 1201, USA
    World J Surg 37:1966-72. 2013
    ..Intraoperative parathyroid hormone monitoring (IOPTH) is a widely used adjunct for primary hyperparathyroidism (pHPT). However, the benefit of IOPTH in familial pHPT, such as in multiple endocrine neoplasia type I (MEN1), remains unclear...
  3. pmc Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screening
    Naris Nilubol
    Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, 10 Center Drive, MSC 1201, Bethesda, MD 20892, USA
    J Transl Med 10:198. 2012
    ..The objective of this study was to identify and validate drugs with antineoplastic effect in ACC cells using a novel quantitative high-throughput drug screening (qHTS) technique...
  4. doi request reprint Preoperative localizing studies for initial parathyroidectomy in MEN1 syndrome: is there any benefit?
    Naris Nilubol
    Endocrine Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Center Drive, MSC1201 Rm 3 3940, Bethesda, MD 20892 1201, USA
    World J Surg 36:1368-74. 2012
    ..The objective of the present study was to evaluate the utility of preoperative localizing studies in patients with MEN1 undergoing initial bilateral neck exploration (BNE) and parathyroidectomy for pHPT...
  5. doi request reprint Molecular pathways associated with mortality in papillary thyroid cancer
    Naris Nilubol
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Surgery 150:1023-31. 2011
    ..Our objectives were to identify molecular pathways associated with unfavorable features and outcomes in patients with PTC...
  6. pmc Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions
    Samira M Sadowski
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md Electronic address
    J Am Coll Surg 218:997-1003. 2014
    ..The aim of this study was to determine whether 18-fluorodeoxyglucose-positron emission tomography ((18)FDG-PET) uptake predicts growth and detects malignant VHL-associated PNENs...
  7. pmc Association of type-O blood with neuroendocrine tumors in multiple endocrine neoplasia type 1
    Allison B Weisbrod
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 98:E109-14. 2013
    ..We recently reported an association between O blood type and the manifestation of pancreatic neuroendocrine tumors in a cohort of patients with Von Hippel-Lindau syndrome...
  8. pmc MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors
    Dhaval Patel
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md Electronic address
    Surgery 154:1224-8; discussion 1229. 2013
    ..The objective of this study was to determine the feasibility and diagnostic accuracy of measuring serum miRNAs in patients with benign and malignant adrenocortical neoplasms...
  9. pmc Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype
    Ryan J Ellis
    Endocrine Oncology Branch R J E, M B, D P, N N, M H, L Z, E K, Genetics Branch Y W, H S S, S D, D C E, P S M, and Laboratory of Pathology M J M, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 and Perelman School of Medicine R J E, University of Pennsylvania, Philadelphia, Pennsylvania 19104
    J Clin Endocrinol Metab 99:E329-37. 2014
    ..Aberrant DNA methylation is known to be a major factor in oncogenesis and cancer progression, but effects of methylation in papillary thyroid cancer (PTC) are not well defined...
  10. pmc Sleeping parathyroid tumor: rapid hyperfunction after removal of the dominant tumor
    Sahzene Yavuz
    Diabetes, Endocrine and Obesity Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:1834-41. 2012
    ..A fall of intraoperative serum PTH by a certain percentage during parathyroid surgery is often used as one criterion for ending the operation...
  11. pmc Clinical utility of functional imaging with ¹⁸F-FDOPA in Von Hippel-Lindau syndrome
    Allison B Weisbrod
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Clinical Research Center, Building 10 CRC, Room 3 3940, 10 Center Drive, MSC 1201, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:E613-7. 2012
    ..There are limited data on the clinical utility of using ¹⁸F-FDOPA PET for identifying neuroendocrine tumors in a high-risk population such as VHL...
  12. pmc Adrenal histologic findings show no difference in clinical presentation and outcome in primary hyperaldosteronism
    Allison B Weisbrod
    Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Ann Surg Oncol 20:753-8. 2013
    ..The goal of this study was to compare the presentation and outcome among patients undergoing adrenalectomy and found to have different histologic features...
  13. ncbi request reprint miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3
    Myriem Boufraqech
    Endocrine Oncology BranchLaboratory of PathologyNational Cancer Institute, National Institutes of Health, Center for Cancer Research, Bethesda, Maryland 20892, USA
    Endocr Relat Cancer 21:517-31. 2014
    ....
  14. pmc Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors
    Suzanne M Inchauste
    Endocrine Oncology Section, Surgery Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, MSC1201 Rm 4W 5940, Bethesda, MD 20892 1201, USA
    World J Surg 36:1517-26. 2012
    ..The authors sought to determine the rate of POPF after enucleation and/or resection of pancreatic neuroendocrine tumors (PNET) and to identify clinical, surgical, or pathologic factors associated with POPF...
  15. pmc Telomere length is shorter in affected members of families with familial nonmedullary thyroid cancer
    Mei He
    Endocrine Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Thyroid 23:301-7. 2013
    ..Thus, the aim of this study was to determine whether telomere length and genes involved in maintaining telomere length are altered in FNMTC...
  16. pmc von Hippel-Lindau disease-associated solid microcystic serous adenomas masquerading as pancreatic neuroendocrine neoplasms
    Simon Turcotte
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda 20892, MD, USA
    Surgery 152:1106-17. 2012
    ..Solid microcystic serous adenoma (SMSA), a rare neoplasm described in VHL patients, can be mistaken for PNEN on imaging...
  17. doi request reprint Association of type O blood with pancreatic neuroendocrine tumors in Von Hippel-Lindau syndrome
    Allison B Weisbrod
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Ann Surg Oncol 19:2054-9. 2012
    ..We analyzed the association of ABO blood type with pancreatic neuroendocrine tumors (PNETs) in a high-risk cohort of patients with Von Hippel-Lindau (VHL) syndrome...
  18. pmc Prospective screening in familial nonmedullary thyroid cancer
    Samira M Sadowski
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Md Electronic address
    Surgery 154:1194-8. 2013
    ..Approximately 8% of nonmedullary thyroid cancers are familial. The optimal age for screening in familial nonmedullary thyroid cancer (FNMTC) is unknown...
  19. pmc Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma
    Meenu Jain
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    Cancer 118:5698-708. 2012
    ..Previous genome-wide expression studies have demonstrated the overexpression of interleukin-13 receptor alpha2 (IL13Rα2) in some human malignancies...
  20. ncbi request reprint The Presence of SDHB Mutations Should Modify Surgical Indications for Carotid Body Paragangliomas
    Ryan J Ellis
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA and Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD
    Ann Surg 260:158-62. 2014
    ..The aim of this study was to determine whether the genetic background of the disease should be incorporated into treatment decision making...
  21. pmc Assessment of tumor growth in pancreatic neuroendocrine tumors in von Hippel Lindau syndrome
    Allison B Weisbrod
    Endocrine Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
    J Am Coll Surg 218:163-9. 2014
    ..Currently, there are limited data on the natural history of these tumors and it is difficult to determine which patients require surgical intervention because the risk of metastatic disease cannot be accurately determined...
  22. pmc Quantitative high-throughput drug screening identifies novel classes of drugs with anticancer activity in thyroid cancer cells: opportunities for repurposing
    Lisa Zhang
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, Clinical Research Center, Building 10 CRC, Room 3 3940, 10 Center Drive, MSC 1201, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:E319-28. 2012
    ..An alternative approach is the exploitation of clinically used and/or bioactive compounds...
  23. pmc DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors
    Nesrin S Rechache
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Clin Endocrinol Metab 97:E1004-13. 2012
    ..Objective: The objective of the study was to determine the methylation profile of normal adrenal cortex and benign and malignant adrenocortical tumors...
  24. pmc Loss of CPSF2 Expression Is Associated with Increased Thyroid Cancer Cellular Invasion and Cancer Stem Cell Population, and More Aggressive Disease
    Naris Nilubol
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
    J Clin Endocrinol Metab 99:E1173-82. 2014
    ..Conclusion: Decreased CPSF2 expression is associated with increased cellular invasion and cancer stem cell population, and more aggressive disease in PTC. ..
  25. pmc Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?
    Ryan J Ellis
    Endocrine Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Am Coll Surg 217:489-96. 2013
    ....
  26. pmc Comparison of 6-18F-fluoro-L-DOPA, 18F-2-deoxy-D-glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease
    Mio Kitano
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, National Institutes of Health, CRC, 10 Center Drive, Bethesda, MD 20892, USA
    Surgery 150:1122-8. 2011
    ..The aim of our study was to determine the accuracy of (18)F-DOPA and (18)F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL)...
  27. pmc What is the best criterion for the interpretation of adrenal vein sample results in patients with primary hyperaldosteronism?
    Richard Webb
    Endocrine Oncology Section, Surgery Branch, National Cancer Institute, Bethesda, MD, USA
    Ann Surg Oncol 19:1881-6. 2012
    ..The objective of this study was to determine which AVS criteria most accurately identify patients with unilateral surgical disease and are associated with significant clinical improvement after adrenalectomy...